Pfizer CEO Read says pharma has a bad rep; Shareholders OK Actavis, Warner Chilcott deal; New cancer drugs make care complex;

@FiercePharma: Italy's Recordati set to buy Spain's Laboratorios Casen Fleet for $122.4M. ICYMI yesterday | Follow @FiercePharma

@EricPFierce: KKR looks to buy stake in Gland Pharma as emotions are running high in India over loss of domestic cos. Report | Follow @EricPFierce

@CarlyHFierce: On why silence from Vivus is not golden. More via Seeking Alpha | Follow @CarlyHFierce

> Pfizer ($PFE) CEO Ian Read acknowledged the industry is not thought of highly by the public, despite providing life-saving meds. Story

> Shareholders have given final approval for generic drugmaker Actavis ($ACT) to buy Warner Chilcott ($WCRX) for $8.5 billion. Report

> India is asking drugmakers there to step up with more production of medicines for tropical diseases. Story

> Perrigo ($PRGO) says the FDA has approved its generic of Johnson & Johnson's ($JNJ) Children's Zyrtec Allergy Syrup. Release

> Biogen Idec ($BIIB) and Amicus Therapeutics ($FOLD) have a new agreement to work on drugs for Parkinson's disease. Story

Medical Device News

@FierceMedDev: Popular yesterday: Intuitive's surgical robots slammed in another study. Article | Follow @FierceMedDev

@DamianFierce: Dako got an FDA warning letter at the plant where it makes its Herceptin companion diagnostic. News | Follow @DamianFierce

@MarkHFierce: Baxter snatched up a tiny startup after closing a nearly $4B deal for Gambro. ICYMI yesterday | Follow @MarkHFierce

> Quest, LabCorp defrauded Medicaid, lawsuit says. News

> Spider silk + carbon nanotubes = next-gen med device part. Item

> KKR might want some help buying Panasonic's $1.5B health biz. Story

Biotech News

@FierceBiotech: ICYMI yesterday: Is there a major R&D overhaul coming at Merck, or just more streamlining? Article | Follow @FierceBiotech

@JohnCFierce: ICYMI: FDA experts endorse new COPD blockbuster from GlaxoSmithKline, Theravance. Story | Follow @JohnCFierce

@EmilyMFierce: This week's issue of FierceBiotech Research: Parkinson's research gets boost; Drug combo tackles coronavirus. Check it out | Follow @EmilyMFierce

@Ry_McBride: Civitas scoops up $38M B round for inhaled Parkinsons drug. News | Follow @Ry_McBride

> OvaScience shares blitzed after FDA steps in to supervise lead product. News

> Merck laterals cancer drug to hungry AstraZeneca, focuses on star programs. Article

> Chimerix reports PhII failure for lead antiviral. Item

Drug Delivery News

@MichaelGFierce: Nanodiamonds deliver brain cancer drugs safely, UCLA team shows. Report | Follow @MichaelGFierce

> Activaero, Chiesi team up for cystic fibrosis drug-device research. News

> Low-cost microspheres take short-lived cancer drugs to brain. Article

> Oramed wins Chinese patent for oral core technology. Item

> CeQur closes $27M round to fund insulin delivery device. Story

Diagnostics News

> Nuclea snatches up Wilex AG Dx subsidiary. Story

> T2 jumps into pivotal trial for Candida assay. News

> NanoString gains FDA blessing for in vitro breast cancer assay. Report

> FDA cites Dx maker Dako for quality system violations. Article

> Study: Abbott blood test spots more female heart attack risks. Item

And Finally... A new study finds that while target cancer drugs are doing more to extend and save patients lives, their complexity is keeping some patients from getting the best care available. Story

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.